UPC Analytics
DEEN
Übersicht · Eingereicht:

ORD_10064/2025

NOVEL ANTITUMORAL USE OF CABAZITAXEL

Prozessuale & UnteranträgeVerfahrensführungsanordnungenMunich LDGeneric Order
  • 2025-05-08Nur prozessualproceduralGeneric Order

    The Munich Local Division judge-rapporteur issued a comprehensive interim conference order in the Sanofi pharmaceutical infringement proceedings against multiple generic manufacturers, covering the substitution of Sanofi Mature IP by Sanofi SA, interim questions of invalidity (including admissibility of counterclaims and late-filed arguments), and procedural scheduling. The order provided preliminary guidance on damages calculation methodology and noted that the EPO Board of Appeal outcome would be relevant to further steps.